;PMID: 12427113
;source_file_926.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..41]
;1)sentence:[e:47..182] = [t:47..182]
;2)section:[e:186..223] = [t:186..223]
;3)section:[e:227..383] = [t:227..383]
;4)sentence:[e:387..534] = [t:387..534]
;5)sentence:[e:536..778] = [t:536..778]
;6)sentence:[e:779..987] = [t:779..987]
;7)sentence:[e:988..1162] = [t:988..1162]
;8)sentence:[e:1164..1237] = [t:1164..1237]
;9)sentence:[e:1239..1370] = [t:1239..1370]
;10)sentence:[e:1371..1458] = [t:1371..1458]
;11)sentence:[e:1459..1632] = [t:1459..1632]
;12)sentence:[e:1633..1812] = [t:1633..1812]
;13)sentence:[e:1813..2084] = [t:1813..2084]
;14)section:[e:2088..2133] = [t:2088..2133]

;section 0 Span:0..41
;Pharmacol Toxicol. 2002 Sep;91(3):129-34.
(SEC
  (FRAG (NNP:[0..9] Pharmacol) (NNP:[10..17] Toxicol) (.:[17..18] .)
        ('':[19..23] 2002) (CC:[24..31] Sep;91-LRB-) (CD:[31..32] 3)
        (-RRB-:[32..33] -RRB-) (CD:[33..37] :129) (::[37..38] -)
        (CD:[38..40] 34) (.:[40..41] .)))

;sentence 1 Span:47..182
;Influence of chloramphenicol on rat hepatic microsomal components and
;biomarkers  of oxidative stress: protective role of antioxidants.
;[60..75]:substance:"chloramphenicol"
;[169..181]:substance:"antioxidants"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[47..56] Influence))
      (PP (IN:[57..59] of)
        (NP (NN:[60..75] chloramphenicol)))
      (PP (IN:[76..78] on)
        (NP
          (NP (NN:[79..82] rat) (JJ:[83..90] hepatic) (JJ:[91..101] microsomal)
              (NNS:[102..112] components))
          (CC:[113..116] and)
          (NP
            (NP (NNS:[117..127] biomarkers))
            (PP (IN:[129..131] of)
              (NP (JJ:[132..141] oxidative) (NN:[142..148] stress)))))))
    (::[148..149] :)
    (NP
      (NP (JJ:[150..160] protective) (NN:[161..165] role))
      (PP (IN:[166..168] of)
        (NP (NNS:[169..181] antioxidants))))
    (.:[181..182] .)))

;section 2 Span:186..223
;Farombi EO, Adaramoye OA, Emerole GO.
(SEC
  (FRAG (NNP:[186..193] Farombi) (NNP:[194..196] EO) (,:[196..197] ,)
        (NNP:[198..207] Adaramoye) (NNP:[208..210] OA) (,:[210..211] ,)
        (NNP:[212..219] Emerole) (NNP:[220..223] GO.)))

;section 3 Span:227..383
;Drug Metabolism and Toxicology Research Laboratories, Department of 
;Biochemistry, College of Medicine, University of Ibadan, Nigeria. 
;ofarombi@skannet.com
(SEC
  (FRAG (NNP:[227..231] Drug) (NNP:[232..242] Metabolism) (CC:[243..246] and)
        (NNP:[247..257] Toxicology) (NNP:[258..266] Research)
        (NNP:[267..279] Laboratories) (,:[279..280] ,)
        (NNP:[281..291] Department) (IN:[292..294] of)
        (NNP:[296..308] Biochemistry) (,:[308..309] ,) (NNP:[310..317] College)
        (IN:[318..320] of) (NNP:[321..329] Medicine) (,:[329..330] ,)
        (NNP:[331..341] University) (IN:[342..344] of) (NNP:[345..351] Ibadan)
        (,:[351..352] ,) (NNP:[353..360] Nigeria) (.:[360..361] .)
        (NNP:[363..379] ofarombi@skannet) (.:[379..383] .com)))

;sentence 4 Span:387..534
;The effects of chloramphenicol and antioxidant vitamins on in vivo and in
;vitro  indices of microsomal drug oxidizing system were examined in rats.
;[402..417]:substance:"chloramphenicol"
;[422..442]:substance:"antioxidant vitamins"
;[490..494]:substance:"drug"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[387..390] The) (NNS:[391..398] effects))
      (PP (IN:[399..401] of)
        (NP
          (NP (NN:[402..417] chloramphenicol))
          (CC:[418..421] and)
          (NP (JJ:[422..433] antioxidant) (NNS:[434..442] vitamins))))
      (PP (IN:[443..445] on)
        (NP
          (NP
            (NP
              (ADJP (FW:[446..448] in) (FW:[449..453] vivo))
              (NML-1 (-NONE-:[453..453] *P*)))
            (CC:[454..457] and)
            (NP
              (ADJP (FW:[458..460] in) (FW:[461..466] vitro))
              (NML-1 (NNS:[468..475] indices))))
          (PP (IN:[476..478] of)
            (NP (JJ:[479..489] microsomal) (NN:[490..494] drug)
                (VBG:[495..504] oxidizing) (NN:[505..511] system))))))
    (VP (VBD:[512..516] were)
      (VP (VBN:[517..525] examined)
        (NP-2 (-NONE-:[525..525] *))
        (PP-LOC (IN:[526..528] in)
          (NP (NNS:[529..533] rats)))))
    (.:[533..534] .)))

;sentence 5 Span:536..778
;Chloramphenicol at doses of 28 mg/kg, 57 mg/kg and 86 mg/kg body weight 
;administered for 10 consecutive days resulted in a dose-dependent decrease in
; body weight, liver weight, relative liver weight and protein content
;compared to  control.
;[536..551]:substance:"Chloramphenicol"
;[564..566]:quantitative-value:"28"
;[567..572]...[596..607]:quantitative-units:"mg/kg"..."body weight"
;[574..576]:quantitative-value:"57"
;[577..582]...[596..607]:quantitative-units:"mg/kg"..."body weight"
;[587..589]:quantitative-value:"86"
;[590..607]:quantitative-units:"mg/kg body weight"
;[626..628]:quantitative-value:"10"
;[641..645]:quantitative-units:"days"
;[741..748]:substance:"protein"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[536..551] Chloramphenicol))
      (PP (IN:[552..554] at)
        (NP
          (NP (NNS:[555..560] doses))
          (PP (IN:[561..563] of)
            (NP
              (NP
                (NP (CD:[564..566] 28) (NN:[567..569] mg))
                (PP (SYM:[569..570] /)
                  (NP
                    (NML (NN:[570..572] kg))
                    (NML-1 (-NONE-:[572..572] *RNR*)))))
              (,:[572..573] ,)
              (NP
                (NP (CD:[574..576] 57) (NN:[577..579] mg))
                (PP (SYM:[579..580] /)
                  (NP
                    (NML (NN:[580..582] kg))
                    (NML-1 (-NONE-:[582..582] *RNR*)))))
              (CC:[583..586] and)
              (NP
                (NP (CD:[587..589] 86) (NN:[590..592] mg))
                (PP (SYM:[592..593] /)
                  (NP
                    (NML (NN:[593..595] kg))
                    (NML-1 (-NONE-:[595..595] *RNR*)))))
              (NML-1 (NN:[596..600] body) (NN:[601..607] weight))))
          (VP (VBN:[609..621] administered)
            (NP (-NONE-:[621..621] *))
            (PP-TMP (IN:[622..625] for)
              (NP (CD:[626..628] 10) (JJ:[629..640] consecutive)
                  (NNS:[641..645] days)))))))
    (VP (VBD:[646..654] resulted)
      (PP (IN:[655..657] in)
        (NP
          (NP
            (NP (DT:[658..659] a)
              (ADJP (NN:[660..664] dose) (HYPH:[664..665] -)
                    (JJ:[665..674] dependent))
              (NN:[675..683] decrease))
            (PP (IN:[684..686] in)
              (NP
                (NP (NN:[688..692] body) (NN:[693..699] weight))
                (,:[699..700] ,)
                (NP (NN:[701..706] liver) (NN:[707..713] weight))
                (,:[713..714] ,)
                (NP (JJ:[715..723] relative) (NN:[724..729] liver)
                    (NN:[730..736] weight))
                (CC:[737..740] and)
                (NP (NN:[741..748] protein) (NN:[749..756] content)))))
          (VP (VBN:[757..765] compared)
            (NP (-NONE-:[765..765] *))
            (PP-CLR (TO:[766..768] to)
              (NP (NN:[770..777] control)))))))
    (.:[777..778] .)))

;sentence 6 Span:779..987
;Chloramphenicol treatment also resulted in a dose-dependent decrease in 
;microsomal phospholipid and a significant increase in cholesterol content 
;causing an increase in cholesterol/phospholipid molar ratio.
;[779..794]:substance:"Chloramphenicol"
;[863..875]:substance:"phospholipid"
;[906..917]:substance:"cholesterol"
;[950..961]:substance:"cholesterol"
;[962..974]:substance:"phospholipid"
(SENT
  (S
    (NP-SBJ (NN:[779..794] Chloramphenicol) (NN:[795..804] treatment))
    (ADVP (RB:[805..809] also))
    (VP (VBD:[810..818] resulted)
      (PP-CLR (IN:[819..821] in)
        (NP
          (NP
            (NP (DT:[822..823] a)
              (ADJP (NN:[824..828] dose) (HYPH:[828..829] -)
                    (JJ:[829..838] dependent))
              (NN:[839..847] decrease))
            (PP (IN:[848..850] in)
              (NP (JJ:[852..862] microsomal) (NN:[863..875] phospholipid))))
          (CC:[876..879] and)
          (NP
            (NP (DT:[880..881] a) (JJ:[882..893] significant)
                (NN:[894..902] increase))
            (PP (IN:[903..905] in)
              (NP (NN:[906..917] cholesterol) (NN:[918..925] content))))))
      (S-ADV
        (NP-SBJ (-NONE-:[925..925] *))
        (VP (VBG:[927..934] causing)
          (NP
            (NP (DT:[935..937] an) (NN:[938..946] increase))
            (PP (IN:[947..949] in)
              (NP
                (NML (NN:[950..961] cholesterol) (SYM:[961..962] /)
                     (NN:[962..974] phospholipid))
                (JJ:[975..980] molar) (NN:[981..986] ratio)))))))
    (.:[986..987] .)))

;sentence 7 Span:988..1162
;The drug produced a  significant reduction in the activity of aniline
;hydroxylase, aminopyrine  N-demethylase, p-nitroanisole O-demethylase and
;ethoxyresorufin O- deethylase.
;[992..996]:substance:"drug"
;[1050..1069]:cyp450:"aniline hydroxylase"
;[1071..1097]:substance:"aminopyrine  N-demethylase"
;[1099..1127]:cyp450:"p-nitroanisole O-demethylase"
;[1132..1161]:cyp450:"ethoxyresorufin O- deethylase"
(SENT
  (S
    (NP-SBJ (DT:[988..991] The) (NN:[992..996] drug))
    (VP (VBD:[997..1005] produced)
      (NP
        (NP (DT:[1006..1007] a) (JJ:[1009..1020] significant)
            (NN:[1021..1030] reduction))
        (PP (IN:[1031..1033] in)
          (NP
            (NP (DT:[1034..1037] the) (NN:[1038..1046] activity))
            (PP (IN:[1047..1049] of)
              (NP
                (NP (NN:[1050..1057] aniline) (NN:[1058..1069] hydroxylase))
                (,:[1069..1070] ,)
                (NP (NN:[1071..1082] aminopyrine)
                    (NN:[1084..1097] N-demethylase))
                (,:[1097..1098] ,)
                (NP (NN:[1099..1113] p-nitroanisole)
                    (NN:[1114..1127] O-demethylase))
                (CC:[1128..1131] and)
                (NP (NN:[1132..1147] ethoxyresorufin) (NN:[1148..1149] O)
                    (HYPH:[1149..1150] -) (NN:[1151..1161] deethylase))))))))
    (.:[1161..1162] .)))

;sentence 8 Span:1164..1237
;Activity of ethoxyresorufin O-deethylase was little affected by the drug.
;[1176..1204]:cyp450:"ethoxyresorufin O-deethylase"
;[1232..1236]:substance:"drug"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1164..1172] Activity))
      (PP (IN:[1173..1175] of)
        (NP (NN:[1176..1191] ethoxyresorufin) (NN:[1192..1204] O-deethylase))))
    (VP (VBD:[1205..1208] was)
      (ADVP (RB:[1209..1215] little))
      (VP (VBN:[1216..1224] affected)
        (NP-1 (-NONE-:[1224..1224] *))
        (PP (IN:[1225..1227] by)
          (NP-LGS (DT:[1228..1231] the) (NN:[1232..1236] drug)))))
    (.:[1236..1237] .)))

;sentence 9 Span:1239..1370
;Chloramphenicol ranging from 10-4-10-6 M similarly produced a concentration 
;dependent inhibition in the activities of the enzymes.
;[1239..1254]:substance:"Chloramphenicol"
;[1268..1277]:quantitative-value:"10-4-10-6"
;[1278..1279]:quantitative-units:"M"
;[1362..1369]:substance:"enzymes"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1239..1254] Chloramphenicol))
      (VP (VBG:[1255..1262] ranging)
        (PP (IN:[1263..1267] from)
          (NP
            (NP
              (QP (CD:[1268..1270] 10) (SYM:[1270..1271] -) (CD:[1271..1272] 4)))
            (PP (HYPH:[1272..1273] -)
              (NP
                (QP (CD:[1273..1275] 10) (SYM:[1275..1276] -)
                    (CD:[1276..1277] 6))
                (NN:[1278..1279] M)))))))
    (ADVP (RB:[1280..1289] similarly))
    (VP (VBD:[1290..1298] produced)
      (NP (DT:[1299..1300] a)
        (ADJP (NN:[1301..1314] concentration) (JJ:[1316..1325] dependent))
        (NN:[1326..1336] inhibition))
      (PP-LOC (IN:[1337..1339] in)
        (NP
          (NP (DT:[1340..1343] the) (NNS:[1344..1354] activities))
          (PP (IN:[1355..1357] of)
            (NP (DT:[1358..1361] the) (NNS:[1362..1369] enzymes))))))
    (.:[1369..1370] .)))

;sentence 10 Span:1371..1458
;Kinetic studies revealed  that chloramphenicol inhibited the enzymes
;non-competitively.
;[1402..1417]:substance:"chloramphenicol"
;[1432..1439]:substance:"enzymes"
(SENT
  (S
    (NP-SBJ (JJ:[1371..1378] Kinetic) (NNS:[1379..1386] studies))
    (VP (VBD:[1387..1395] revealed)
      (SBAR (IN:[1397..1401] that)
        (S
          (NP-SBJ (NN:[1402..1417] chloramphenicol))
          (VP (VBD:[1418..1427] inhibited)
            (NP (DT:[1428..1431] the) (NNS:[1432..1439] enzymes))
            (ADVP-MNR (AFX:[1440..1443] non) (HYPH:[1443..1444] -)
                      (RB:[1444..1457] competitively))))))
    (.:[1457..1458] .)))

;sentence 11 Span:1459..1632
;alpha-Tocopherol,  beta-carotene and ascorbic acid decreased the
;chloramphenicol inhibition of the  enzymes within the range of 70 to 81%,
;45-63% and 55 to 75% respectively.
;[1459..1475]:substance:"alpha-Tocopherol"
;[1478..1491]:substance:"beta-carotene"
;[1496..1509]:substance:"ascorbic acid"
;[1524..1539]:substance:"chloramphenicol"
;[1559..1566]:substance:"enzymes"
;[1587..1596]:quantitative-value:"70 to 81%"
;[1598..1604]:quantitative-value:"45-63%"
;[1609..1618]:quantitative-value:"55 to 75%"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1459..1475] alpha-Tocopherol))
      (,:[1475..1476] ,)
      (NP (NN:[1478..1491] beta-carotene))
      (CC:[1492..1495] and)
      (NP (JJ:[1496..1504] ascorbic) (NN:[1505..1509] acid)))
    (VP (VBD:[1510..1519] decreased)
      (NP
        (NP (DT:[1520..1523] the) (NN:[1524..1539] chloramphenicol)
            (NN:[1540..1550] inhibition))
        (PP (IN:[1551..1553] of)
          (NP (DT:[1554..1557] the) (NNS:[1559..1566] enzymes))))
      (PP (IN:[1567..1573] within)
        (NP
          (NP (DT:[1574..1577] the) (NN:[1578..1583] range))
          (PP (IN:[1584..1586] of)
            (NP
              (NP
                (QP (CD:[1587..1589] 70) (TO:[1590..1592] to)
                    (CD:[1593..1595] 81))
                (NN:[1595..1596] %))
              (,:[1596..1597] ,)
              (NP
                (QP (CD:[1598..1600] 45) (HYPH:[1600..1601] -)
                    (CD:[1601..1603] 63))
                (NN:[1603..1604] %))
              (CC:[1605..1608] and)
              (NP
                (QP (CD:[1609..1611] 55) (TO:[1612..1614] to)
                    (CD:[1615..1617] 75))
                (NN:[1617..1618] %))
              (ADVP (RB:[1619..1631] respectively)))))))
    (.:[1631..1632] .)))

;sentence 12 Span:1633..1812
;Also,  the antioxidant vitamins attenuated the chloramphenicol-induced
;formation of  malondialdehyde by 60%, 53% and 56% and lipid hydroperoxide by
;60%, 54%, and 54%  respectively
;[1644..1664]:substance:"antioxidant vitamins"
;[1680..1695]:substance:"chloramphenicol"
;[1718..1733]:substance:"malondialdehyde"
;[1737..1740]:quantitative-value:"60%"
;[1742..1745]:quantitative-value:"53%"
;[1750..1753]:quantitative-value:"56%"
;[1758..1777]:substance:"lipid hydroperoxide"
;[1781..1784]:quantitative-value:"60%"
;[1786..1789]:quantitative-value:"54%"
;[1795..1798]:quantitative-value:"54%"
(SENT
  (S
    (ADVP (RB:[1633..1637] Also))
    (,:[1637..1638] ,)
    (NP-SBJ (DT:[1640..1643] the)
       (JJ:[1644..1655] antioxidant) (NNS:[1656..1664] vitamins))
    (VP
      (VP (VBD:[1665..1675] attenuated)
        (NP=2
          (NP (DT:[1676..1679] the)
            (ADJP (NN:[1680..1695] chloramphenicol) (HYPH:[1695..1696] -)
                  (VBN:[1696..1703] induced))
            (NN:[1704..1713] formation))
          (PP (IN:[1714..1716] of)
            (NP=3 (NN:[1718..1733] malondialdehyde))))
        (PP-EXT=4 (IN:[1734..1736] by)
          (NP
            (NP (CD:[1737..1739] 60) (NN:[1739..1740] %))
            (,:[1740..1741] ,)
            (NP (CD:[1742..1744] 53) (NN:[1744..1745] %))
            (CC:[1746..1749] and)
            (NP (CD:[1750..1752] 56) (NN:[1752..1753] %)))))
      (CC:[1754..1757] and)
      (VP
        (NP=2 (NN:[1758..1763] lipid) (NN:[1764..1777] hydroperoxide))
        (PP-EXT=4 (IN:[1778..1780] by)
          (NP
            (NP (CD:[1781..1783] 60) (NN:[1783..1784] %))
            (,:[1784..1785] ,)
            (NP (CD:[1786..1788] 54) (NN:[1788..1789] %))
            (,:[1789..1790] ,) (CC:[1791..1794] and)
            (NP (CD:[1795..1797] 54) (NN:[1797..1798] %))
            (ADVP (RB:[1800..1812] respectively))))))))

;sentence 13 Span:1813..2084
;The results indicate that the effect of chloramphenicol on  cytochrome P450
;drug oxidizing enzyme components is related to the action of the  drug
;presumably, via free radical mechanism and that co-administration with 
;antioxidant vitamins can attenuate its toxic action.
;[1853..1868]:substance:"chloramphenicol"
;[1873..1910]:cyp450:"cytochrome P450 drug oxidizing enzyme"
;[1955..1959]:substance:"drug"
;[1976..1988]:substance:"free radical"
;[2032..2052]:substance:"antioxidant vitamins"
(SENT
  (S
    (NP-SBJ (DT:[1813..1816] The) (NNS:[1817..1824] results))
    (VP (VBP:[1825..1833] indicate)
      (SBAR
        (SBAR (IN:[1834..1838] that)
          (S
            (NP-SBJ-1
              (NP (DT:[1839..1842] the) (NN:[1843..1849] effect))
              (PP (IN:[1850..1852] of)
                (NP (NN:[1853..1868] chloramphenicol)))
              (PP (IN:[1869..1871] on)
                (NP
                  
                  (NML (NN:[1873..1883] cytochrome) (NN:[1884..1888] P450))
                  (ADJP (NN:[1889..1893] drug) (VBG:[1894..1903] oxidizing))
                  (NN:[1904..1910] enzyme)
                  (NNS:[1911..1921] components))))
            (VP (VBZ:[1922..1924] is)
              (VP (VBN:[1925..1932] related)
                (NP-1 (-NONE-:[1932..1932] *))
                (PP-CLR (TO:[1933..1935] to)
                  (NP
                    (NP (DT:[1936..1939] the) (NN:[1940..1946] action))
                    (PP (IN:[1947..1949] of)
                      (NP (DT:[1950..1953] the) (NN:[1955..1959] drug)))))
                (ADVP (RB:[1960..1970] presumably))
                (,:[1970..1971] ,)
                (PP-MNR (IN:[1972..1975] via)
                  (NP
                    (NML (JJ:[1976..1980] free) (JJ:[1981..1988] radical))
                    (NN:[1989..1998] mechanism)))))))
        (CC:[1999..2002] and)
        (SBAR (IN:[2003..2007] that)
          (S
            (NP-SBJ
              (NP (AFX:[2008..2010] co) (HYPH:[2010..2011] -)
                  (NN:[2011..2025] administration))
              (PP (IN:[2026..2030] with)
                (NP (JJ:[2032..2043] antioxidant) (NNS:[2044..2052] vitamins))))
            (VP (MD:[2053..2056] can)
              (VP (VB:[2057..2066] attenuate)
                (NP (PRP$:[2067..2070] its) (JJ:[2071..2076] toxic)
                    (NN:[2077..2083] action))))))))
    (.:[2083..2084] .)))

;section 14 Span:2088..2133
;PMID: 12427113 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2088..2092] PMID) (::[2092..2093] :) (CD:[2094..2102] 12427113)
        (NN:[2103..2104] -LSB-) (NNP:[2104..2110] PubMed) (::[2111..2112] -)
        (NN:[2113..2120] indexed) (IN:[2121..2124] for)
        (NNP:[2125..2133] MEDLINE-RSB-)))
